Sign in

    Alex Aylen

    Research Analyst at Canaccord Genuity

    Alex Aylen is Head of Equities for Canaccord Genuity’s capital markets business in the UK and Europe, leveraging over 15 years of experience in the financial industry. She specializes in European equity markets, providing sales and trading coverage for a diverse set of corporate and institutional clients, with a particular focus on growth companies. Alex began her career at Cenkos Securities, where she held the position of Head of Sales for the Growth Companies Team before joining Canaccord Genuity in 2018 as Head of Corporate Sales, later being promoted to her current role in 2021. She holds a BSc in Economics from Queen Mary University of London, is a CFA charterholder, and brings a track record of leadership within leading capital markets institutions.

    Alex Aylen's questions to PACIFIC BIOSCIENCES OF CALIFORNIA (PACB) leadership

    Alex Aylen's questions to PACIFIC BIOSCIENCES OF CALIFORNIA (PACB) leadership • Q1 2025

    Question

    Alex Aylen from Canaccord Genuity questioned the key factors behind pausing the high-throughput short-read sequencer development and asked about any observed cannibalization of Revio by Vega.

    Answer

    Christian Henry, President and CEO, explained the decision was driven by the macroeconomic environment, the need to focus resources on the competitively stronger long-read market, and rapid R&D progress on the long-read side. On the second point, Henry stated they are not seeing direct cannibalization, but rather customers opting for the more affordable Vega due to current funding constraints, with the expectation they will adopt Revio later. He noted that about 50% of Vega customers are new to PacBio.

    Ask Fintool Equity Research AI